Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
AstraZeneca
Dow
Express Scripts
McKesson

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,106,158

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,106,158
Title:Compositions and methods for fusion protein separation
Abstract: The present invention relates to compositions and methods for fusion protein separation utilizing a peptide linker comprising a novel thrombin cleavage site.
Inventor(s): Kim; Sujeong (Seoul, KR), Kim; Jong-Mook (Seoul, KR), Xu; Song Shan (Beijing, CN)
Assignee: ViroMed Co., Ltd. (KR)
Application Number:12/431,687
Patent Claims:1. A chimeric protein comprising a protein of interest, a fusion partner, and a peptide linker interposed there between, wherein said protein of interest is linked to the N-terminus of said peptide linker and said fusion partner is linked to the C-terminus of said peptide linker or said protein of interest is linked to the C-terminus of said peptide linker and said fusion partner is linked to the N-terminus of said peptide linker, wherein said peptide linker consists of the sequence: X1-X2-Ser-Pro-X3-X4-X5 (SEQ ID NO: 44) wherein, X1 is two to ten amino acid residues that are the same or different from each other; X2 is glycine; X3 is arginine or lysine; X4 is alanine or glycine; and X5 is a non-acidic amino acid, wherein (a) said fusion partner is an affinity peptide; (b) said protein of interest is selected from the group consisting of human interleukin (IL)-11, thymosin .beta.4, thymosin .alpha.1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-18, Protease-activated receptor 1(PAR1), PAR3, PAR4, RANTES, stromal cell-derived factor-1.alpha., monocyte chemotactic protein, stem cell factor, FLT-3L, parathyroid hormone, thrombopoietin, epidermal growth factor, basic fibroblast growth factor, insulin-like growth factor, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, macrophage colony stimulating factor, platelet-derived growth factor, transforming growth factor (TGF)-.beta.1, tumor necrosis factor (TNF)-.alpha., interferon (IFN)-.alpha., IFN-.beta., IFN-.gamma., hepatocyte growth factor, vascular endothelial growth factor and immunoglobulin heavy chain, wherein said chimeric protein is non-naturally occurring; or (c) said fusion partner is an affinity peptide and said protein of interest is selected from the group consisting of human interleukin (IL)-11, thymosin .beta.4, thymosin .alpha.1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-18, Protease-activated receptor 1 (PAR1), PAR3, PAR4, RANTES, stromal cell-derived factor-1.alpha., monocyte chemotactic protein, stem cell factor, FLT-3L, parathyroid hormone, thrombopoietin, epidermal growth factor, basic fibroblast growth factor, insulin-like growth factor, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, macrophage colony stimulating factor, platelet-derived growth factor, transforming growth factor (TGF)-.beta.1, tumor necrosis factor (TNF)-.alpha., interferon (IFN)-.alpha., IFN-.beta., IFN-.gamma., hepatocyte growth factor, vascular endothelial growth factor and immunoglobulin heavy chain.

2. The chimeric protein of claim 1, wherein X1 is four to ten amino acid residues.

3. The chimeric protein of claim 2, wherein X1 comprises proline and arginine.

4. The chimeric protein of claim 1, wherein X5 is selected from the group consisting of serine, alanine, asparagine, valine, leucine, isoleucine, lysine, phenylalanine, tyrosine, and tryptophan.

5. The chimeric protein of claim 1, wherein said affinity peptide is selected from the group consisting of glutathione-S-transferase (GST), maltose binding protein (MBP), hexahistidine, T7 peptide, ubiquitin, Flag peptide, c-myc peptide, polyarginine, polycysteine, polyphenylalanine, BTag, galactose binding domain, cellulose binding domain (CBD), thioredoxin, staphylococcal protein A, streptococcal protein G, calmodulin, beta-galactosidase, chloramphenicol acetyltransferase, S-peptide, streptavidin, His-tag, and Strep-tag.

6. The chimeric protein of claim 1, wherein said protein of interest is selected from the group consisting of human IL11, thymosin .beta.4, IL-6 and PAR4.

7. The chimeric protein of claim 1, wherein said protein of interest is linked to the N-terminus of said peptide linker and said fusion partner is linked to the C-terminus of said peptide linker.

8. The chimeric protein of claim 1, wherein said protein of interest is linked to the C-terminus of said peptide linker and said fusion partner is linked to the N-terminus of said peptide linker.

Details for Patent 8,106,158

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial ViroMed Co., Ltd. (KR) 2025-04-20 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial ViroMed Co., Ltd. (KR) 2025-04-20 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial ViroMed Co., Ltd. (KR) 2025-04-20 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial ViroMed Co., Ltd. (KR) 2025-04-20 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Merck
Baxter
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.